伏立诺他联合放疗及维持治疗儿童弥漫性内生型脑桥胶质瘤的I/II期试验
儿童肿瘤协作组(COG)开展I/II期试验,评估伏立诺他同步放疗及后续维持治疗在新诊断儿童弥漫性内生型脑桥胶质瘤(DIPG)中的推荐II期剂量、毒性和疗效。同步放疗期推荐II期剂量为230 mg/m2/天(周一至周五),伏立诺他耐受良好,但无事件生存风险较历史COG数据目标风险无显著降低(P=0.32,单侧)。1年无事件生存率为5.85%(95%CI 1.89-13.1%),1年总生存率为39.2%(95%CI 27.8-50.5%)。
要点
- 伏立诺他同步放疗的推荐II期剂量为230 mg/m2/天,周一至周五给药。
- 伏立诺他耐受良好,仅8.6%患者因毒性永久停药,未中断放疗。
- 无事件生存风险较历史COG数据目标风险无显著降低(P=0.32,单侧)。
核心结论
- 伏立诺他同步放疗后单药维持治疗在新诊断儿童DIPG中耐受良好,但未能改善结局。
研究设计与样本
- I/II期试验由儿童肿瘤协作组(COG)开展,纳入新诊断儿童弥漫性内生型脑桥胶质瘤(DIPG)患者。
- II期部分在推荐II期剂量下6例患者及额外64例患者纳入疗效评估。
主要发现
- 伏立诺他同步放疗的推荐II期剂量为230 mg/m2/天,周一至周五每周给药。
- 伏立诺他耐受良好,未中断放疗,仅8.6%患者因毒性永久停药。
- 无事件生存风险较历史COG数据目标风险无显著降低(P=0.32,单侧)。
- 1年无事件生存率为5.85%(95%CI 1.89-13.1%),1年总生存率为39.2%(95%CI 27.8-50.5%)。
关键数值与推荐
- 同步放疗期伏立诺他推荐II期剂量为230 mg/m2/天,周一至周五每周给药。
- 放疗方案为54 Gy分30次。
临床怎么用
- 伏立诺他同步放疗及维持治疗方案在该人群中耐受良好,但未显示疗效优于历史数据,不支持其作为改善结局的常规选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A phase I/II trial of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor, was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) through the Children's Oncology Group (COG) to: 1) determine the recommended phase II dose (RP2D) of vorinostat given concurrently with radiation therapy; 2) document the toxicities of continuing vorinostat as maintenance therapy after radiation; and 3) to determine the efficacy of this regimen by comparing the risk of progression or death with a historical model from past COG trials. METHODS: Vorinostat was given once daily, Monday through Friday, during radiation therapy (54 Gy in 30 fractions), and then continued at 230 mg/m2 daily for a maximum of twelve 28-day cycles. RESULTS: Twelve patients enrolled in the phase I study; the RP2D of vorinostat given concurrently with radiation was 230 mg/m2/day, Monday through Friday weekly. The six patients enrolled at the RP2D and an additional 64 patients enrolled in the phase II study contributed to the efficacy assessment. Although vorinostat was well-tolerated, did not interrupt radiation therapy, and was permanently discontinued in only 8.6% of patients due to toxicities, risk for EFS-event was not significantly reduced compared with the target risk derived from historical COG data (P = 0.32; 1-sided). The 1-year EFS was 5.85% (95% CI 1.89-13.1%) and 1-year OS was 39.2% (27.8-50.5%). CONCLUSIONS: Vorinostat given concurrently with radiation followed by vorinostat monotherapy was well tolerated in children with newly diagnosed DIPG but failed to improve outcome.
引用
- Su JM, Kilburn LB, Mansur DB, et al. Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. Neuro Oncol. 2022. PMID: 34347089. doi:10.1093/neuonc/noab188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。